Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DICE DICE Therapeutics	$47.55	$47.31	$15.08 ▼ $47.90	$2.27B	1.03	1.03 million shs	N/A
PINC Premier	$20.98 +0.1%	$22.33	$17.23 ▼ $23.56	$1.73B	0.56	1.30 million shs	108,547 shs
RARE Ultragenyx Pharmaceutical	$26.05 -1.0%	$35.65	$26.00 ▼ $60.37	$2.48B	0.26	975,958 shs	441,078 shs
VALN Valneva	$6.44 -1.8%	$6.10	$3.62 ▼ $8.66	$547.55M	1.74	42,895 shs	2,554 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DICE DICE Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PINC Premier	0.00%	-0.62%	-5.03%	+8.44%	+7.05%
RARE Ultragenyx Pharmaceutical	0.00%	-10.84%	-29.16%	-25.68%	-38.17%
VALN Valneva	0.00%	+5.93%	+13.68%	-3.02%	-13.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PINC Premier	1.9537 of 5 stars	1.0	1.0	2.5	0.0	3.4	2.5	1.9
RARE Ultragenyx Pharmaceutical	4.3772 of 5 stars	4.5	1.0	0.0	3.8	2.2	2.5	0.6
VALN Valneva	1.9992 of 5 stars	3.5	3.0	0.0	0.0	2.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DICE DICE Therapeutics	0.00	N/A	N/A	N/A
PINC Premier	2.00	Hold	$22.20	5.82% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$83.64	221.12% Upside
VALN Valneva	3.00	Buy	$15.50	140.87% Upside

Current Analyst Ratings Breakdown

Latest DICE, RARE, VALN, and PINC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/21/2025	PINC Premier	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00 ➝ $24.00
5/15/2025	PINC Premier	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$19.00 ➝ $22.00
5/9/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$64.00 ➝ $65.00
5/8/2025	PINC Premier	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$19.00 ➝ $22.00
5/8/2025	VALN Valneva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DICE DICE Therapeutics	$1.13M	2,008.50	N/A	N/A	$10.86 per share	4.38
PINC Premier	$1.35B	1.28	$3.64 per share	5.76	$18.68 per share	1.12
RARE Ultragenyx Pharmaceutical	$560.23M	4.40	N/A	N/A	$2.76 per share	9.44
VALN Valneva	$183.52M	2.98	$0.10 per share	67.04	$2.41 per share	2.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DICE DICE Therapeutics	-$83.89M	-$2.34	N/A	N/A	N/A	N/A	-22.01%	-20.79%	N/A
PINC Premier	$119.54M	$0.57	36.84	15.77	N/A	5.68%	8.79%	4.86%	8/19/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
VALN Valneva	-$13.25M	-$1.19	N/A	N/A	N/A	-43.08%	-43.05%	-16.23%	8/12/2025 (Estimated)

Latest DICE, RARE, VALN, and PINC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	VALN Valneva	-$0.27	N/A	N/A	N/A	$46.28 million	N/A
8/7/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	VALN Valneva	-$0.40	-$0.13	+$0.27	-$0.13	$41.80 million	$51.79 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DICE DICE Therapeutics	N/A	N/A	N/A	N/A	N/A
PINC Premier	$0.84	4.00%	N/A	147.37%	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
VALN Valneva	N/A	N/A	N/A	N/A	N/A

Latest DICE, RARE, VALN, and PINC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/24/2025	PINC Premier	quarterly	$0.21	4.2%	5/30/2025	6/1/2025	6/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DICE DICE Therapeutics	N/A	25.88	32.44
PINC Premier	N/A	0.65	0.65
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
VALN Valneva	0.92	2.70	2.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DICE DICE Therapeutics	N/A
PINC Premier	74.41%
RARE Ultragenyx Pharmaceutical	97.67%
VALN Valneva	11.39%

Insider Ownership

Company	Insider Ownership
DICE DICE Therapeutics	4.90%
PINC Premier	0.96%
RARE Ultragenyx Pharmaceutical	5.50%
VALN Valneva	14.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DICE DICE Therapeutics	71	47.73 million	45.39 million	Not Optionable
PINC Premier	2,900	82.34 million	81.55 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable
VALN Valneva	700	85.09 million	72.41 million	Not Optionable

DICE, RARE, VALN, and PINC Headlines

Recent News About These Companies

Valneva (NASDAQ:VALN) Shares Gap Up - Here's What Happened

July 15, 2025 | marketbeat.com

Valneva's chikungunya vaccine suspension gets lifted for older adults

July 11, 2025 | msn.com

Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly

July 11, 2025 | globenewswire.com

Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults

July 11, 2025 | reuters.com

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus

June 26, 2025 | globenewswire.com

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance

June 25, 2025 | globenewswire.com

Valneva Scotland earns prestigious global health and safety award

June 24, 2025 | msn.com

Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measure

June 10, 2025 | indiaeducationdiary.inI

UK's MHRA suspends Valneva's chikungunya vaccine for elderly

June 10, 2025 | reuters.com

Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children

June 10, 2025 | pharmexec.comP

UK restricts use of Valneva chikungunya vaccine for safety review

June 10, 2025 | yahoo.com

UK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)

June 10, 2025 | msn.com

Valneva reports data from Phase II chikungunya vaccine trial in children

June 6, 2025 | finance.yahoo.com

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

June 5, 2025 | globenewswire.com

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

June 4, 2025 | globenewswire.com

Valneva to Participate at U.S. and European Investor Conferences in June

May 26, 2025 | globenewswire.com

US CDC accepts recommendations for chikungunya vaccines

May 21, 2025 | msn.com

London man among thousands who've rolled up their sleeves to trial Lyme disease vaccine

May 19, 2025 | cbc.ca

US Advises Older Travelers to Avoid Chikungunya Vaccine

May 16, 2025 | infectiousdiseaseadvisor.comI

FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors

May 15, 2025 | pharmexec.comP

FDA, CDC recommend pause in Valneva chikungunya vaccine for older adults

May 13, 2025 | cidrap.umn.eduC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
These 3 Rare Earth Stocks Are Surging Alongside MP Materials
By Leo Miller | July 19, 2025
View These 3 Rare Earth Stocks Are Surging Alongside MP Materials
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
By Ryan Hasson | July 7, 2025
View Top 5 Undervalued Dividend Stocks With Strong Payout Potential

DICE, RARE, VALN, and PINC Company Descriptions

DICE Therapeutics NASDAQ:DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.

Premier NASDAQ:PINC

$20.98 +0.03 (+0.14%)

As of 11:17 AM Eastern

Premier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina.

Ultragenyx Pharmaceutical NASDAQ:RARE

$26.05 -0.26 (-1.00%)

As of 11:17 AM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Valneva NASDAQ:VALN

$6.44 -0.12 (-1.76%)

As of 11:11 AM Eastern

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time